Logo image
Back
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
Journal article   Open access   Peer reviewed

Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Danai Dima, James A Davis, Nausheen Ahmed, Xuefei Jia, Aishwarya Sannareddy, Hira Shaikh, Leyla Shune, Gurbakhash Kaur, Jack Khouri, Aimaz Afrough, …
Transplantation and cellular therapy, Vol.30(3), pp.308.e1-308.e13
03/2024
DOI: 10.1016/j.jtct.2023.12.016
PMID: 38151105
url
https://doi.org/10.1016/j.jtct.2023.12.016View
Published (Version of record) Open Access

Abstract

Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for relapsed-refractory multiple myeloma (RRMM) on the basis of the phase I/II MajesTEC-1 trial. Herein, we report clinical outcomes with standard-of-care teclistamab in a real-world RRMM population. A total of 106 patients from five academic centers who received teclistamab from 8/2022 to 8/2023 were included in this retrospective analysis; 83% of whom would have been considered ineligible for the MajesTec-1 trial. All patients were triple-class exposed, 64% were penta-class refractory, and 53% had received prior BCMA-directed therapy. Cytokine release syndrome was observed in 64% of patients and only one event was grade ≥3, while immune effector cell-associated neurotoxicity syndrome was observed in 14% of patients (three events were grade 3-4). One-third (31%) of patients experienced at least one infection, with nearly half of these infections graded as severe (grade ≥3). The overall response rate (ORR) and complete or better response rate were 66% and 29%, respectively. The ORR was 47%, 59% and 68% for patients with extramedullary disease (EMD), prior BCMA-directed therapy, and penta-refractory disease, respectively. At a median follow-up of 3.8 months, the median progression-free survival (PFS) was 5.4 months (95% CI, 3.4 months-not reached), while median overall survival was not reached. Patients with Eastern Cooperative Oncology Group performance status ≥2, EMD, and age ≤70 years had inferior PFS on multivariable analysis. Our study demonstrates reasonable safety and good efficacy of teclistamab in patients with RRMM treated in the real-world setting.
 refractory T-cell engager bispecific relapsed BCMA Multiple Myeloma

Details

Metrics

44 Record Views
Logo image